MammaPrint uses a 70-gene profile to classify breast cancer patients as 'low' or 'high' risk for developing distant metastasis in a 10-year period.
The CupPrint test, meantime, is intended to identify the primary tumor in patients with cancer of unknown primary.
Financial terms of the agreement were not disclosed.